Follow the people · Insider
Kristian Reich
Kristian Reich files insider transactions with the SEC as a chief scientific officer of MoonLake Immunotherapeutics (MLTX). We hold 8 disclosed purchases and sales filed since 7 April 2023, 8 of them in the last 90 days.
- Files forMLTX
- Disclosed buys and sells8 in all, 8 in the last 90 days
- Last disclosure29 July 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 5 April 2023 — 27 July 2026Chief Scientific Officer · MoonLake Immunotherapeutics (MLTX)48 Form 4 lines · source: SEC Form 4
Everything they disclosed
48 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,100 shares of MoonLake ImmunotherapeuticsSEC Form 429 July 2026Class A ordinary shares, par value $0.0001 per share · traded 27 July 2026 · filed 29 July 2026
- ▼ sold on the open market 50,000 shares of MoonLake ImmunotherapeuticsSEC Form 423 July 2026Class A ordinary shares, par value $0.0001 per share · traded 21 July 2026 · filed 23 July 2026
- ▼ sold on the open market 2,448 shares of MoonLake ImmunotherapeuticsSEC Form 423 July 2026Class A ordinary shares, par value $0.0001 per share · traded 22 July 2026 · filed 23 July 2026
- ▼ sold on the open market 43,700 shares of MoonLake ImmunotherapeuticsSEC Form 421 July 2026Class A ordinary shares, par value $0.0001 per share · traded 20 July 2026 · filed 21 July 2026
- ▼ sold on the open market 16,105 shares of MoonLake ImmunotherapeuticsSEC Form 420 July 2026Class A ordinary shares, par value $0.0001 per share · traded 15 July 2026 · filed 20 July 2026
- ▼ sold on the open market 50,000 shares of MoonLake ImmunotherapeuticsSEC Form 417 June 2026Class A ordinary shares, par value $0.0001 per share · traded 15 June 2026 · filed 17 June 2026
- ▼ sold on the open market 50,000 shares of MoonLake ImmunotherapeuticsSEC Form 417 June 2026Class A ordinary shares, par value $0.0001 per share · traded 16 June 2026 · filed 17 June 2026
- ▼ sold on the open market 50,000 shares of MoonLake ImmunotherapeuticsSEC Form 417 June 2026Class A ordinary shares, par value $0.0001 per share · traded 17 June 2026 · filed 17 June 2026
- was granted 520,342 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 7 January 2026 · filed 9 January 2026
- was granted 520,342 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 49 January 2026Stock Option (Right to Buy) · traded 7 January 2026 · filed 9 January 2026
- converted 1,052 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 422 December 2025Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 19 December 2025 · filed 22 December 2025
- converted 35,389 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class A ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- returned to the issuer 35,389 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class C ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- ▼ sold on the open market 130,000 shares of MoonLake ImmunotherapeuticsSEC Form 410 December 2025Class A ordinary shares, par value $0.0001 per share · traded 8 December 2025 · filed 10 December 2025
- ▼ sold on the open market 72,908 shares of MoonLake ImmunotherapeuticsSEC Form 410 December 2025Class A ordinary shares, par value $0.0001 per share · traded 9 December 2025 · filed 10 December 2025
- converted 1,456 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 44 September 2025Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 20 January 2025 · filed 4 September 2025
- converted 48,978 shares of MoonLake ImmunotherapeuticsSEC Form 44 September 2025Class A ordinary shares, par value $0.0001 per share · traded 2 September 2025 · filed 4 September 2025
- returned to the issuer 48,978 shares of MoonLake ImmunotherapeuticsSEC Form 44 September 2025Class C ordinary shares, par value $0.0001 per share · traded 2 September 2025 · filed 4 September 2025
- was granted 139,273 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 March 2025Stock Option (Right to Buy) · traded 27 February 2025 · filed 3 March 2025
- converted 3,328 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 422 January 2025Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 20 January 2025 · filed 22 January 2025
- converted 111,949 shares of MoonLake ImmunotherapeuticsSEC Form 422 January 2025Class A ordinary shares, par value $0.0001 per share · traded 20 January 2025 · filed 22 January 2025
- returned to the issuer 111,949 shares of MoonLake ImmunotherapeuticsSEC Form 422 January 2025Class C ordinary shares, par value $0.0001 per share · traded 20 January 2025 · filed 22 January 2025
- ▼ sold on the open market 29,491 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 27 February 2024 · filed 29 February 2024
- ▼ sold on the open market 29,431 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 27 February 2024 · filed 29 February 2024
- ▼ sold on the open market 31,910 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 28,090 shares of MoonLake ImmunotherapeuticsSEC Form 429 February 2024Class A ordinary shares, par value $0.0001 per share · traded 28 February 2024 · filed 29 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 422 February 2024Class A ordinary shares, par value $0.0001 per share · traded 20 February 2024 · filed 22 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 422 February 2024Class A ordinary shares, par value $0.0001 per share · traded 20 February 2024 · filed 22 February 2024
- ▼ sold on the open market 509 shares of MoonLake ImmunotherapeuticsSEC Form 422 February 2024Class A ordinary shares, par value $0.0001 per share · traded 21 February 2024 · filed 22 February 2024
- ▼ sold on the open market 569 shares of MoonLake ImmunotherapeuticsSEC Form 422 February 2024Class A ordinary shares, par value $0.0001 per share · traded 21 February 2024 · filed 22 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 14 February 2024 · filed 16 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 14 February 2024 · filed 16 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 15 February 2024 · filed 16 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 15 February 2024 · filed 16 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 16 February 2024 · filed 16 February 2024
- ▼ sold on the open market 10,000 shares of MoonLake ImmunotherapeuticsSEC Form 416 February 2024Class A ordinary shares, par value $0.0001 per share · traded 16 February 2024 · filed 16 February 2024
- converted 75,136 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 October 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 1 October 2023 · filed 3 October 2023
- converted 1,248 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 October 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 1 October 2023 · filed 3 October 2023
- converted 2,527,477 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class A ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- returned to the issuer 2,527,477 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class C ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- converted 41,981 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class A ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- returned to the issuer 41,981 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class C ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- converted 14,864 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 47 April 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 5 April 2023 · filed 7 April 2023
- converted 2,916 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 47 April 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 5 April 2023 · filed 7 April 2023
- converted 500,006 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class A ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- returned to the issuer 500,006 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class C ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- converted 98,090 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class A ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- returned to the issuer 98,090 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class C ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.